Peginterferon and Mental impairment - a phase IV clinical study of FDA data

Summary:

Mental impairment is reported as a side effect among people who take Peginterferon (peginterferon alfa-2a; ribavirin), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Ribavirin, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Mental impairment when taking Peginterferon. It is created by eHealthMe based on reports of 13,689 people who have side effects when taking Peginterferon from the FDA, and is updated regularly.

What is Peginterferon?

Peginterferon has active ingredients of peginterferon alfa-2a; ribavirin. It is often used in hepatitis c. eHealthMe is studying from 13,778 Peginterferon users. Check the latest studies of Peginterferon.

What is Mental impairment?

Mental impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition) is found to be associated with 1,340 drugs and 1,315 conditions by eHealthMe. Check the latest studies of Mental impairment.

On Jul, 08, 2026

13,689 people reported to have side effects when taking Peginterferon.
Among them, 11 people (0.08%) have Mental impairment.

Could Peginterferon cause Mental impairment?

Among these 11 people:

How long have people been on Peginterferon when they have Mental impairment? *

What is the gender of people who have Mental impairment when taking Peginterferon? *

female: 54.55 %
male: 45.45 %

What is the age of people who have Mental impairment when taking Peginterferon? *

What are other drugs people take besides Peginterferon? *

What are other side effects people have besides Mental impairment? *

Fatigue (feeling of tiredness): 5 people, 45.45%
Disturbance In Attention: 5 people, 45.45%
Joint Pain: 4 people, 36.36%
Memory Loss: 4 people, 36.36%
Muscle Aches (muscle pain): 4 people, 36.36%
Neuropathy Peripheral (surface nerve damage): 4 people, 36.36%
Pain: 3 people, 27.27%
Eye Pain: 3 people, 27.27%
Headache (pain in head): 3 people, 27.27%
Dry Skin: 3 people, 27.27%

What are the existing conditions these people have? *

Stress And Anxiety: 3 people, 27.27%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 3 people, 27.27%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 18.18%
Gastritis (inflammation of stomach): 2 people, 18.18%
Depression: 2 people, 18.18%
Sleep Disorder: 1 person, 9.09%
Procedural Pain: 1 person, 9.09%
Pain: 1 person, 9.09%
Neck Pain: 1 person, 9.09%
Hiv Infection: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Peginterferon and have Mental impairment?

- Check whether Mental impairment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Peginterferon:

Peginterferon (13,778 reports)

Mental impairment treatments and more:

Mental impairment (27,670 reports)

How severe was Mental impairment and when was it recovered:

Mental impairment in Peginterferon

Expand to all the drugs that have ingredients of peginterferon alfa-2a; ribavirin:

Mental impairment and drugs with ingredients of peginterferon alfa-2a; ribavirin (11 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Peginterferon:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mental impairment:

Mental impairment (1,340 drugs)

Browse all the conditions that are associated with Mental impairment:

Mental impairment (1,315 conditions)

Related publications that referenced our studies

Momtaz YA, Hamid TA, Ibrahim R, "The impact of mild cognitive impairment on sexual activity", American Journal of Alzheimer's Disease & Other Dementias?, 2013 Jan .
Momtaz YA, Hamid TA, Ibrahim R, "The impact of mild cognitive impairment on sexual activity", American Journal of Alzheimer's Disease & Other Dementias?, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on peginterferon alfa-2a; ribavirin (the active ingredients of Peginterferon) and Peginterferon (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.